Walder Wyss advised Novo Holdings on the acquisition of Catalent
30. Januar 2025 – Novo Holdings A/S, a leading global life science investor, has completed in December 2024 its previously announced acquisition of Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, in an all-cash transaction with a total enterprise value of approximately $16.5 billion. In connection with the transaction, Novo Holdings will sell three of Catalent’s nearly 50 global sites to Novo Nordisk A/S. Catalent is a leading partner to some of the most innovative biopharma companies in the world. Over the past 10 years, Catalent has assisted in 50% of all FDA approvals, demonstrating the strength of its industry-leading clinical supply management capabilities.
Walder Wyss advised Novo Holdings A/S on the Swiss aspects of the transaction. The team was co-led by Luc Defferrard (Partner, Corporate/M&A) and Iliana Djagova (Counsel, Corporate/M&A) and further included Simone Wetzstein (Partner, Employment Law), Fabienne Limacher (Partner, Tax), Sylvia Anthamatten (Counsel, IP/IT), Julia Lehner (Counsel, Real Estate), Fabian Looser (Counsel, Employment), Erik Lanz (Senior Associate, Corporate/M&A), Simon Olstein (Senior Associate, Life Sciences) and Christoph Burckhardt (Associate, Corporate/M&A).